XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

    NEXT STORY
    PM360 Magazine Announces Winners of 2019 Trailblazer Awards
    PREV STORY
    Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017

    DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology ...

    author_avatar
    NASDAQ Market News

    Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

    WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage ...

    author_avatar
    NASDAQ Market News

    Vital Therapies Enrolls First Subject in VTL-308

    SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic ...

    author_avatar
    NASDAQ Market News